Mogamulizumab + DA-EPOCH Protocol + CHOEP protocol
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T Cell Lymphoma
Conditions
T Cell Lymphoma, T-cell Lymphoma
Trial Timeline
Oct 9, 2024 → Nov 1, 2027
NCT ID
NCT05996185About Mogamulizumab + DA-EPOCH Protocol + CHOEP protocol
Mogamulizumab + DA-EPOCH Protocol + CHOEP protocol is a phase 2 stage product being developed by Kyowa Kirin for T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05996185. Target conditions include T Cell Lymphoma, T-cell Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in T Cell Lymphoma were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05996185 | Phase 2 | Recruiting |
Competing Products
20 competing products in T Cell Lymphoma